Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

European Union — European Medicines Agency & United States — Food and Drug Administration

60 shared events · Importance 5 · Last updated Sep 24, 2026

Importance
5
Shared Events
60
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
70
Tech
European Union — European Medicines Agency: The European Union — European Medicines Agency granted PRIME designation for Privosegtor, another significant regulatory milestone that supports its development in Europe.
United States — Food and Drug Administration: The United States — Food and Drug Administration granted Breakthrough Therapy designation for Privosegtor, a key regulatory milestone that accelerates its development and potential approval.
Jun 11, 2026 · 7 articles
68
Regulatory
European Union — European Medicines Agency: The EMA validated Roche's application for Enspryng in MOGAD in Europe, advancing the parallel European regulatory pathway.
United States — Food and Drug Administration: The FDA granted Priority Review and will decide on approval by 10 January 2027, making it the key regulatory gatekeeper for the drug's U.S. launch.
Sep 09, 2026 · 6 articles
65
Regulatory
European Union — European Medicines Agency: The EMA initiated a phased review of daraxonrasib, accelerating the assessment process for a potential new pancreatic cancer therapy.
United States — Food and Drug Administration: The FDA is reviewing a rolling NDA for daraxonrasib under a priority voucher program, which could expedite U.S. approval.
Jul 07, 2026 · 7 articles
65
Tech
European Union — European Medicines Agency: The European Union — European Medicines Agency has released detailed guidance on computerized systems and data management, stressing the importance of secure, attributable and contemporaneous records, which accelerates the move toward automation.
United States — Food and Drug Administration: The United States — Food and Drug Administration encourages the adoption of advanced manufacturing technologies and continuous production models, reinforcing the shift from reactive to proactive compliance strategies in the pharmaceutical industry.
Apr 07, 2026 · 8 articles
57
Regulatory
European Union — European Medicines Agency: Estimated NAION could affect up to one in 10,000 people with diabetes using GLP-1 medicines and required updated warnings on semaglutide product information in 2025. Its action sets a precedent that US regulators have not followed.
United States — Food and Drug Administration: US regulator that has not added a NAION warning to GLP-1 labels but is conducting an ongoing review through its Sentinel Initiative. Its eventual decision could reshape labeling and prescribing for the entire drug class.
Sep 21, 2026 · 20 articles
57
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency conditionally approved Imlifidase and requested the PAES study, which has now been successfully completed, paving the way for a full marketing authorization application.
United States — Food and Drug Administration: The United States — Food and Drug Administration accepted the Biologics License Application for imlifidase in February 2026, indicating potential future market expansion for the drug in the US.
May 27, 2026 · 6 articles
57
Regulatory
European Union — European Medicines Agency: Immunome plans to submit a Marketing Authorization Application to the EMA by end of 2026, making the EMA a future regulatory body for varegacestat in Europe.
United States — Food and Drug Administration: The FDA accepted the NDA for review and will decide on approval by April 28, 2027, playing a critical regulatory role in the event.
Jul 08, 2026 · 6 articles
57
Regulatory
European Union — European Medicines Agency: The EMA is also reviewing the combination for the same indication.
United States — Food and Drug Administration: The FDA accepted the application for Priority Review and will decide by Q4 2026.
Jul 22, 2026 · 6 articles
57
Regulatory
European Union — European Medicines Agency: The EMA validated the Marketing Authorization Application for AVT16 and AVT80, supporting European regulatory progress.
United States — Food and Drug Administration: The FDA accepted the BLA for review, a key regulatory step; its decision will determine market entry.
Aug 31, 2026 · 9 articles
52
Regulatory
European Union — European Medicines Agency: The European Union — European Medicines Agency approved the Spikevax formula, expanding Moderna's market access in Europe.
United States — Food and Drug Administration: The FDA granted approval for Moderna's updated vaccines, playing a central regulatory role in the event.
Aug 27, 2026 · 6 articles
46
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) has granted Orphan Drug designation to zeleciment basivarsen, indicating Dyne Therapeutics' pursuit of approval pathways outside of the U.S.
United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) is the regulatory body responsible for granting Accelerated Approval and Priority Review for zeleciment basivarsen, which is crucial for its potential U.S. launch. The FDA has already granted Breakthrough Therapy, Orphan Drug, and Fast Track designations to zeleciment basivarsen.
Jun 03, 2026 · 6 articles
46
Business
European Union — European Medicines Agency: The EMA has granted PRIME designation to iopofosine I 131, which may facilitate regulatory review in Europe, though no immediate actions were reported.
United States — Food and Drug Administration: The FDA is the regulatory body for the planned NDA submission of iopofosine I 131 under the Accelerated Approval Program, a critical milestone for Cellectar.
Jul 30, 2026 · 6 articles
45
Tech
European Union — European Medicines Agency: The European Union — European Medicines Agency has granted Lonvoguran ziclumeran Priority Medicines (PRIME) Designation, which supports the development of medicines that address unmet medical needs.
United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) has granted Lonvoguran ziclumeran Orphan Drug and RMAT Designation, indicating its potential importance and expediting its review process.
Jun 01, 2026 · 6 articles
45
Regulatory
European Union — European Medicines Agency: The EMA is conducting a rolling review of daraxonrasib, which could lead to a marketing authorization application in Europe, expanding the drug's global reach.
United States — Food and Drug Administration: The FDA granted expedited approval to daraxonrasib, marking a regulatory milestone and demonstrating its commitment to accelerating cancer treatments. The approval was issued 6.5 months ahead of schedule, reflecting the agency's priority review process.
Aug 26, 2026 · 92 articles
42
Regulatory
European Union — European Medicines Agency: Its CHMP committee issued the positive opinion that drives the event, reinforcing the agency's role as the gatekeeper for EU drug approvals.
United States — Food and Drug Administration: The US regulator has granted orphan drug designation to glepaglutide and will assess a future New Drug Application supported by the EASE-5 trial.
Sep 18, 2026 · 6 articles
42
Regulatory
European Union — European Medicines Agency: The European Union — European Medicines Agency has granted Orphan Drug Designation and Advanced Therapy Medicinal Product designation to Deramiocel, indicating its potential importance in Europe, though the current event focuses on U.S. regulatory review.
United States — Food and Drug Administration: The United States — Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee is convening a meeting to review Paragon Therapeutics' Biologics License Application for Deramiocel, which is a critical step in the regulatory approval process for the drug.
Jun 26, 2026 · 6 articles
42
Regulatory
European Union — European Medicines Agency: The European Union — European Medicines Agency>>> has validated a Marketing Authorization Application for AVT16 and AVT80, indicating progress in European markets.
United States — Food and Drug Administration: The United States — Food and Drug Administration>>> accepted the Biologics License Application for AVT16, initiating the review process for this proposed interchangeable biosimilar.
Jun 08, 2026 · 11 articles
42
Regulatory
European Union — European Medicines Agency: Granted orphan drug designation; not directly involved in the FDA setback.
United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.
Jul 27, 2026 · 305 articles
40
Business
European Union — European Medicines Agency: The EMA granted PRIME status to PentixaFor, providing enhanced support for its development and approval in European Union — Europe.
United States — Food and Drug Administration: The FDA granted Fast Track designation to PentixaFor, facilitating its development and regulatory review.
Jul 15, 2026 · 10 articles
37
Business
European Union — European Medicines Agency: The EMA's September 2025 reflection paper on patient experience data is cited as the key regulatory backdrop making the launch timely, with final guidance expected soon.
United States — Food and Drug Administration: The FDA's continued advancement of Patient-Focused Drug Development and guidance on patient experience information is cited as part of the regulatory shift supporting the launch.
Sep 17, 2026 · 6 articles
32
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency>>> is involved in the approval process for Imlifidase>>>, with a payment contingent on its filing acceptance.
United States — Food and Drug Administration: The United States — Food and Drug Administration>>> accepted the Biologics License Application for imlifidase in the US, indicating future market potential outside the current deal.
May 19, 2026 · 7 articles
30
Tech
European Union — European Medicines Agency: The European Union — European Medicines Agency granted IBM System/4 Pi Orphan Drug designation, which can expedite its development and review process in Europe.
United States — Food and Drug Administration: The United States — Food and Drug Administration granted IBM System/4 Pi Orphan Drug designation, which can expedite its development and review process.
Jun 24, 2026 · 6 articles
30
Regulatory
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) is mentioned as a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the European Union.
United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) is a target for a Biologics License Application (BLA) submission in early 2027 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the United States. The FDA also granted Fast Track designation for XPro1595.
Jun 25, 2026 · 6 articles
30
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency has granted orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification, and priority medicines (PRIME) designation to Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel.
United States — Food and Drug Administration: The United States — Food and Drug Administration has granted orphan drug designation and regenerative medicine advanced therapy (RMAT) designations to Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel.
Jun 10, 2026 · 6 articles
30
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency has granted Orphan Drug Designation to G2B-002 for DIPG and pGBM, providing a positive regulatory status for the drug's development in Europe.
United States — Food and Drug Administration: The United States — Food and Drug Administration has granted Orphan Drug Designation to G2B-002 for DIPG and pGBM, which is a positive regulatory status for the drug's development.
Jun 08, 2026 · 7 articles
30
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency granted Priority Medicines (PRIME) designation to Oculis's Privosegtor, indicating its importance.
United States — Food and Drug Administration: The United States — Food and Drug Administration granted Breakthrough Therapy designation to Oculis's Privosegtor, highlighting its potential.
Jun 08, 2026 · 6 articles
30
Business
European Union — European Medicines Agency: Granted PRIME designation for lacutamab in Sézary syndrome, supporting accelerated assessment.
United States — Food and Drug Administration: Granted Fast Track and Breakthrough Therapy designations to lacutamab, facilitating its development and review.
Aug 10, 2026 · 10 articles
28
Regulatory
European Union — European Medicines Agency: The EMA is the regulatory body validating and assessing the application. Its decision will determine market access in Europe.
United States — Food and Drug Administration: The FDA is mentioned in the context of a separate approval for Pfizer's Hympavzi, not directly related to this event.
Aug 14, 2026 · 12 articles
28
Regulatory
European Union — European Medicines Agency: The EMA's advisory committee recommended approval, which preceded the International — European Commission's decision.
United States — Food and Drug Administration: The FDA previously approved trofinetide in the US, establishing its efficacy and safety.
Aug 24, 2026 · 7 articles
28
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency has granted zilganersen Orphan Drug designation for Alexander disease.
United States — Food and Drug Administration: The United States — Food and Drug Administration is currently reviewing zilganersen with a PDUFA action date of September 22, 2026, and has granted it Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations.
Jun 25, 2026 · 6 articles
+ 30 more events View on Dashboard
ERGEN INTELLIGENCE
Explore this relationship live

Track how European Union — European Medicines Agency and United States — Food and Drug Administration interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.